SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
India
· Delayed Price · Currency is INR 235.69
-4.55 (-1.89%)
Apr 30, 2025, 3:29 PM IST
SMS Pharmaceuticals Revenue
SMS Pharmaceuticals had revenue of 1.73B INR in the quarter ending December 31, 2024, with 7.35% growth. This brings the company's revenue in the last twelve months to 7.80B, up 27.32% year-over-year. In the fiscal year ending March 31, 2024, SMS Pharmaceuticals had annual revenue of 7.09B with 35.86% growth.
Revenue (ttm)
7.80B
Revenue Growth
+27.32%
P/S Ratio
2.68
Revenue / Employee
6.52M
Employees
1,197
Market Cap
20.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 7.09B | 1.87B | 35.86% |
| Mar 31, 2023 | 5.22B | 21.77M | 0.42% |
| Mar 31, 2022 | 5.20B | -433.03M | -7.69% |
| Mar 31, 2021 | 5.63B | 1.49B | 35.93% |
| Mar 31, 2020 | 4.14B | -524.43M | -11.24% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
SMS Pharmaceuticals News
- 7 months ago - Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus - Business Upturn
- 7 months ago - SMS Pharmaceuticals receives EDQM certification to supply Ibuprofen in Europe - Business Upturn